Advertisement

Nivolumab in Combination With Cisplatin Plus Gemcitabine in Treatment of Unresectable or Metastatic Urothelial Carcinoma


Advertisement
Get Permission

On March 6, 2024, nivolumab (Opdivo) was approved for use in combination with cisplatin and gemcitabine for first-line treatment of patients with unresectable or metastatic urothelial carcinoma.1

OF NOTE

Nivolumab has warnings/precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryofetal toxicity.

Supporting Efficacy Data

Approval was based on the open-label CheckMate 901 trial ­(ClinicalTrials.gov identifier NCT03036098), in which 608 patients were randomly assigned to receive nivolumab in combination with cisplatin plus gemcitabine for up to six cycles followed by nivolumab for up to 2 years (n = 304) or cisplatin plus gemcitabine for up to six cycles. In both groups, patients discontinuing cisplatin alone were permitted to receive ­carboplatin. Randomization was stratified by tumor PD-L1 expression and presence of liver metastasis.

Median overall survival was 21.7 months (95% confidence interval [CI] = 18.6–26.4 months) in the nivolumab-plus-chemotherapy group vs 18.9 months (95% CI = 14.7–22.4 months) in the chemotherapy-alone group (hazard ratio [HR] = 0.78, 95% CI = 0.63–0.96, P = .0171). Median progression-free survival on blinded independent central review was 7.9 months (95% CI = 7.6–9.5 months) in the nivolumab group vs 7.6 months (95% CI = 6.0–7.8 months) in the chemotherapy-alone group (HR = 0.72, 95% CI = 0.59–0.88, P = .0012).

How It Is Used

The recommended nivolumab dose for this indication follows:

  • 360 mg every 3 weeks in combination with cisplatin and gemcitabine every 3 weeks for up to six cycles, followed by
  • 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity, or a maximum of 2 years from the first dose.

Safety Profile

In CheckMate 901, the most common adverse events of any grade in the nivolumab-plus-chemotherapy group were nausea (52% vs 53% in the control group), fatigue (48% vs 43%), musculoskeletal pain (33% vs 21%), constipation (30% vs 28%), decreased appetite (30% vs 19%), rash (25% vs 7%), vomiting (23% vs 19%), and peripheral neuropathy (20% vs 14%). The most common grade 3 or 4 adverse events in the nivolumab group included urinary tract infection (8% vs 8%), renal dysfunction (6% vs 2%), and fatigue (4% vs 4%).

Serious adverse events occurred in 48% of patients in the nivolumab-plus-chemotherapy group, most commonly urinary tract infection (4.9%), acute kidney injury (4.3%), anemia (3%), pulmonary embolism (2.6%), sepsis (2.3%), and platelet count decrease (2.3%). Adverse events led to discontinuation of nivolumab or chemotherapy in 30% of patients. Fatal adverse reactions occurred in 3.6% of patients in the nivolumab-plus-chemotherapy group, including sepsis in 1%.

Nivolumab has warnings/precautions for immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, dermatologic adverse reactions, and nephritis and renal dysfunction; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation; and embryofetal toxicity. Patients should be advised not to breastfeed while receiving nivolumab. 

REFERENCE

1. Opdivo (nivolumab) injection, for intravenous use, prescribing information, Bristol-Myers Squibb Company, March 2024. Available at https://www.opdivohcp.com. Accessed March 21, 2024.

 


Advertisement

Advertisement




Advertisement